Using artificially intelligent text messaging to improve health behaviors to reduce cardiovascular risk: study protocol for a pragmatic randomized control trial.
Amy D Lu, Catia Chavez, Stacie L Daugherty...
https://pubmed.ncbi.nlm.nih.gov/41721367/Actively Recruiting
Led by University of Colorado, Denver · Updated on 2024-03-22
2100
Participants Needed
3
Research Sites
17 weeks
Total Duration
Researchers are evaluating three strategies to reduce cardiovascular disease risk factors in patients facing health disparities, including ethnic minorities, low-income groups, and those with limited English proficiency. The study focuses on improving self-management of chronic cardiovascular conditions by targeting the American Heart Associations Lifes Essential 8 factors blood glucose, cholesterol, blood pressure, physical activity, body mass index, diet, and smoking. The main goal is to see if text messaging, AI chatbot messaging, or chatbot messaging combined with pharmacist support can improve patient outcomes and self-management. Participants will be randomly assigned to one of three groups. The first group receives generic weekly text messages for nine weeks. The second group receives four weekly interactive messages from an AI chatbot that encourages engagement and tailored support on LE8 topics. The third group receives the same interactive AI chatbot messages plus proactive pharmacist outreach to address any uncontrolled risk factors. The trial runs over several years at health centers serving diverse populations experiencing health disparities. Participants will be followed for 12 months after randomization. Researchers will measure changes in the LE8 health score and individual cardiovascular risk factors. They will also assess medication adherence, self-efficacy, clinical outcomes like hospitalizations, and healthcare use. Data collection includes pharmacy records, clinical events, and patient questionnaires. The study aims to identify effective communication methods to support patients in managing cardiovascular risks, with attention to social and cultural factors.
CONDITIONS
Using AI Text Messaging to Improve AHA's Life's Essential 8 Health Behaviors
L
Lisa Sandy, MA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of Colorado, Denver
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Interactive AI chatbot messages | Generic weekly text messages | AI chatbot plus pharmacist support | Usual care (no messaging) |
|---|---|---|---|---|
| What it is | Weekly interactive AI chatbot text messaging personalized to each LE8 topic over 9 weeks. | A behavioral arm using simple, weekly unidirectional text messages for 9 weeks. | Interactive AI chatbot messaging plus proactive pharmacist support. | Typical care involving no structured messaging to support LE8 behaviors. |
| Role in trial | Investigational arm testing interactive AI messaging. | Active comparator arm. | Investigational arm with added pharmacist outreach. | Represents common clinical practice without messaging. |
| Primary use | To engage participants interactively on LE8 topics with tailored support. | To prompt behavior change via simple weekly reminders. | To combine AI messaging with pharmacist-led engagement to support self-management. | To reflect self-management support as typically delivered without messaging. |
| How it is given or performed | Four interactive texts per week on the weekly LE8 topic inviting engagement with chatbot, over 9 weeks. | One unidirectional text message sent weekly for 9 weeks. | Same as AI chatbot arm plus proactive outreach from pharmacists. | Usual self-management pathways without structured messaging. |
| Evidence status | AI-enabled cardiovascular interventions have shown benefit on process measures but evidence on health outcomes is limited. | Text messaging can modestly improve cardiovascular risk factors like blood pressure and BMI. | Combination digital plus pharmacist support is plausible but lacks direct trial evidence to date. | No structured messaging: standard outcomes depend on routine clinical care without messaging support. |
| Important risks | Likely minimal risk; digital messaging interventions generally safe though data are limited. | Minimal risk from unidirectional texting. | Likely minimal risk for combined intervention; no safety data published yet. | Standard clinical self-management carries routine risk as per usual care. |
| Important limitations | Evidence limited on long-term clinical outcomes; implementation heterogeneity and bias concerns exist. | Effects modest; may not address multiple LE8 domains comprehensively. | Novel combination lacking prior evidence; feasibility and scalability unknown. | Lacks structured support; may result in insufficient patient engagement with LE8 behaviors. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person or remote) for eligibility assessment
Duration - 9 weeks
Participants receive one of three text messaging interventions to support self-management of cardiovascular risk factors: generic weekly messages, interactive AI chatbot messages with weekly engagement, or interactive AI chatbot messages plus proactive pharmacist support.
Weekly text message interactions over 9 weeks
Duration - Up to 12 months after treatment
Participants are monitored for changes in cardiovascular health behaviors and risk factors up to 12 months after randomization.
Baseline and 12-month follow-up visits
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
3
Have more questions? Get in touch with our team for quick support
Amy D Lu, Catia Chavez, Stacie L Daugherty...
https://pubmed.ncbi.nlm.nih.gov/41721367/University of Colorado, Denver
Lead Sponsor
National Heart, Lung, and Blood Institute (NHLBI)
Collaborating Sponsor